Triomics ARR grows 10x year-over-year with $22M raised

Triomics, which focuses on automating oncology workflows such as clinical trial matching and tumor registry reporting, has achieved remarkable traction.

Its ARR grew 10x year-over-year, driven by deep integration into the operations of prestigious cancer centers like Memorial Sloan Kettering (MSK), MD Anderson, Yale Cancer Center, and Mount Sinai.

The company raised a $22M Series B led by Battery Ventures to further accelerate its growth. The tumor registry reporting feature serves as a key entry point for adoption, addressing a major operational bottleneck at cancer centers.

Despite competition from data-heavy companies like Tempus and Flatiron, Triomics has differentiated by focusing on day-to-day oncology staff workflows, a harder-to-displace niche supported by a validated 2025 ASCO study showcasing OncoLLM's superior trial matching accuracy.